Which has preferable earnings & valuation, IMM or BVXP?

Bioventix has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuPharma N/A N/A -£2.51M -£0.37 N/A Bioventix £12.54M 7.03 £8.12M £140.52 12.01

Is IMM or BVXP more profitable?

ImmuPharma has a net margin of 3,519.56% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets ImmuPharma 3,519.56% -1,397.44% -43.00% Bioventix 59.30% 65.83% 54.07%

Does the media prefer IMM or BVXP?

In the previous week, ImmuPharma had 1 more articles in the media than Bioventix. MarketBeat recorded 3 mentions for ImmuPharma and 2 mentions for Bioventix. Bioventix's average media sentiment score of 1.27 beat ImmuPharma's score of -0.44 indicating that Bioventix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Bioventix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, MPH or IMM?

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A ImmuPharma N/A N/A -£2.51M -£0.37 N/A

Do analysts prefer 4BB or IMM?

4basebio presently has a consensus target price of GBX 1,400, suggesting a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher possible upside, equities analysts clearly believe 4basebio is more favorable than ImmuPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 ImmuPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or IMM more profitable?

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% ImmuPharma 3,519.56% -1,397.44% -43.00%

Which has stronger valuation & earnings, FARN or IMM?

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A ImmuPharma N/A N/A -£2.51M -£0.37 N/A

ImmuPharma (IMM) Competitors

GBX 3.72 +0.02 (+0.54%)

As of 12:03 PM Eastern

Compare

IMM vs. BVXP, MPH, 4BB, FARN, and OBI

Should you buy ImmuPharma stock or one of its competitors? MarketBeat compares ImmuPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmuPharma include Bioventix (BVXP), Mereo BioPharma Group plc (MPH.L) (MPH), 4basebio (4BB), Faron Pharmaceuticals Oy (FARN), and Ondine Biomedical (OBI). These companies are all part of the "biotechnology" industry.

How does ImmuPharma compare to Bioventix?

ImmuPharma (LON:IMM) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

In the previous week, ImmuPharma had 1 more articles in the media than Bioventix. MarketBeat recorded 3 mentions for ImmuPharma and 2 mentions for Bioventix. Bioventix's average media sentiment score of 1.27 beat ImmuPharma's score of -0.44 indicating that Bioventix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bioventix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 6.5% of ImmuPharma shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmuPharma has a net margin of 3,519.56% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-1,397.44%	-43.00%
Bioventix	59.30%	65.83%	54.07%

ImmuPharma has a beta of 3.004, indicating that its stock price is 200% more volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market.

Bioventix has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A
Bioventix	£12.54M	7.03	£8.12M	£140.52	12.01

Summary

Bioventix beats ImmuPharma on 8 of the 12 factors compared between the two stocks.

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

ImmuPharma has a net margin of 3,519.56% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A
ImmuPharma	3,519.56%	-1,397.44%	-43.00%

In the previous week, ImmuPharma had 3 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 3 mentions for ImmuPharma and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 beat ImmuPharma's score of -0.44 indicating that Mereo BioPharma Group plc (MPH.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group plc (MPH.L)	Neutral
ImmuPharma	Neutral

6.1% of ImmuPharma shares are owned by institutional investors. 6.5% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

Summary

ImmuPharma beats Mereo BioPharma Group plc (MPH.L) on 5 of the 9 factors compared between the two stocks.

How does ImmuPharma compare to 4basebio?

4basebio (LON:4BB) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, ImmuPharma had 3 more articles in the media than 4basebio. MarketBeat recorded 3 mentions for ImmuPharma and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 beat ImmuPharma's score of -0.44 indicating that 4basebio is being referred to more favorably in the media.

Company	Overall Sentiment
4basebio	Neutral
ImmuPharma	Neutral

0.9% of 4basebio shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 6.5% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

4basebio has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.004, suggesting that its stock price is 200% more volatile than the broader market.

4basebio presently has a consensus target price of GBX 1,400, suggesting a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher possible upside, equities analysts clearly believe 4basebio is more favorable than ImmuPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ImmuPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
ImmuPharma	3,519.56%	-1,397.44%	-43.00%

ImmuPharma has lower revenue, but higher earnings than 4basebio. ImmuPharma is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	50.31	-£9.84M	-£109.00	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

Summary

4basebio beats ImmuPharma on 8 of the 15 factors compared between the two stocks.

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

Faron Pharmaceuticals Oy has a beta of 1.108, meaning that its stock price is 11% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.004, meaning that its stock price is 200% more volatile than the broader market.

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 6.5% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, ImmuPharma had 3 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 3 mentions for ImmuPharma and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 beat ImmuPharma's score of -0.44 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
ImmuPharma	Neutral

ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
ImmuPharma	3,519.56%	-1,397.44%	-43.00%

Summary

ImmuPharma beats Faron Pharmaceuticals Oy on 8 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Ondine Biomedical?

ImmuPharma (LON:IMM) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, ImmuPharma had 3 more articles in the media than Ondine Biomedical. MarketBeat recorded 3 mentions for ImmuPharma and 0 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 0.00 beat ImmuPharma's score of -0.44 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuPharma	Neutral
Ondine Biomedical	Neutral

ImmuPharma has a net margin of 3,519.56% compared to Ondine Biomedical's net margin of -1,117.06%. ImmuPharma's return on equity of -1,397.44% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-1,397.44%	-43.00%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

Ondine Biomedical has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A
Ondine Biomedical	C$2.05M	3,803.45	-C$424.66K	-C$7.00	N/A

ImmuPharma has a beta of 3.004, meaning that its share price is 200% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.322, meaning that its share price is 68% less volatile than the broader market.

6.1% of ImmuPharma shares are owned by institutional investors. Comparatively, 29.3% of Ondine Biomedical shares are owned by institutional investors. 6.5% of ImmuPharma shares are owned by company insiders. Comparatively, 37.4% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ImmuPharma and Ondine Biomedical tied by winning 6 of the 12 factors compared between the two stocks.

Get ImmuPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMM vs. The Competition

Export

Metric	ImmuPharma	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£23.21M	£496.86M	£6.80B	£2.77B
Dividend Yield	0.77%	3.86%	2.68%	6.16%
P/E Ratio	-10.05	3.18	25.79	366.66
Price / Sales	N/A	7,182.40	550.58	85,978.63
Price / Cash	20.50	13.13	46.33	27.87
Price / Book	5.76	88.54	10.77	7.76
Net Income	-£2.51M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-15.55%	1.95%	3.15%	-0.71%
1 Month Performance	-14.62%	0.80%	2.34%	-1.20%
1 Year Performance	37.78%	72.01%	33.42%	65.93%

ImmuPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMM ImmuPharma	N/A	GBX 3.72 +0.5%	N/A	+67.3%	£23.21M	N/A	N/A	13	News Coverage Gap Down
BVXP Bioventix	N/A	GBX 1,745 -4.4%	N/A	-36.4%	£91.18M	£12.54M	12.42	12	News Coverage Positive News Insider Trade
MPH Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	N/A	£89.76M	N/A	N/A	50	Gap Down
4BB 4basebio	N/A	GBX 550 +4.8%	GBX 1,400 +154.5%	-49.7%	£85.17M	£1.69M	N/A	101	Gap Up
FARN Faron Pharmaceuticals Oy	N/A	GBX 42.15 -3.1%	N/A	-78.5%	£84.10M	N/A	N/A	34	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IMM) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuPharma (IMM) Competitors

IMM vs. BVXP, MPH, 4BB, FARN, and OBI

How does ImmuPharma compare to Bioventix?

Summary

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Summary

How does ImmuPharma compare to 4basebio?

Summary

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Summary

How does ImmuPharma compare to Ondine Biomedical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuPharma (IMM) Competitors

IMM vs. BVXP, MPH, 4BB, FARN, and OBI

How does ImmuPharma compare to Bioventix?

Does the media prefer IMM or BVXP?

Do insiders & institutionals have more ownership in IMM or BVXP?

Is IMM or BVXP more profitable?

Which has more volatility & risk, IMM or BVXP?

Which has preferable earnings & valuation, IMM or BVXP?

Summary

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Is MPH or IMM more profitable?

Does the media refer more to MPH or IMM?

Do institutionals & insiders hold more shares of MPH or IMM?

Which has better earnings & valuation, MPH or IMM?

Summary

How does ImmuPharma compare to 4basebio?

Does the media prefer 4BB or IMM?

Do institutionals and insiders have more ownership in 4BB or IMM?

Which has more risk & volatility, 4BB or IMM?

Do analysts prefer 4BB or IMM?

Is 4BB or IMM more profitable?

Which has higher valuation and earnings, 4BB or IMM?

Summary

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Which has stronger valuation & earnings, FARN or IMM?

Which has more risk & volatility, FARN or IMM?

Do institutionals and insiders have more ownership in FARN or IMM?

Does the media favor FARN or IMM?

Is FARN or IMM more profitable?

Summary

How does ImmuPharma compare to Ondine Biomedical?

Does the media prefer IMM or OBI?

Is IMM or OBI more profitable?

Which has preferable earnings and valuation, IMM or OBI?

Which has more volatility & risk, IMM or OBI?

Do insiders & institutionals hold more shares of IMM or OBI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools